Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR91 | A4D1P6 | 7/20 | 0.57 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | OGG1 | O15527 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22438947 | 0.85 | HDAC1 (0.49) | HDAC1HDAC3HDAC2HDAC6OGG1 | |
| SCHEMBL20358898 | 0.82 | PDE2A (0.52) | HDAC1HDAC3HDAC6ALDH1A1LMNA | |
| SCHEMBL20898400 | 0.79 | WDR91 (0.54) | WDR91CXCR3HDAC1HDAC3HDAC2 | |
| SCHEMBL22439020 | 0.79 | HDAC1 (0.48) | HDAC1HDAC3HDAC2HDAC6OGG1 | |
| SCHEMBL16249346 | 0.79 | WDR91 (0.53) | WDR91CXCR3HDAC1HDAC3HDAC2 | |
| SCHEMBL22685263 | 0.78 | HDAC3 (0.44) | WDR91CXCR3HDAC1HDAC3HDAC2 | |
| SCHEMBL27857949 | 0.77 | WDR91 (0.48) | WDR91CXCR3HDAC1HDAC3HDAC2 | |
| SCHEMBL23908251 | 0.76 | CTSL (0.47) | CXCR3HDAC1KDM4EALDH1A1LMNA | |
| SCHEMBL20899151 | 0.75 | FLT1 (0.52) | WDR91CXCR3HDAC1TRPA1KDM4E | |
| SCHEMBL15258671 | 0.75 | HDAC3 (0.47) | WDR91CXCR3HDAC1HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3709986-B1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-11498904-B2 | Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME LLC (US) | 2022-11-15 | — | — | US | disclosed |
| US-20210317091-A1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-10-14 | — | — | US | disclosed |
| EP-3709986-A1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2020-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317091-A1 | NOVEL SUBSTITUTED BIARYL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | IDO1, IDO2, KYNU | WDR91 1642/4885CXCR3 741/4885HDAC1 68/4885 |
| US-11498904-B2 | Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | IDO1, IDO2, INMT | WDR91 1729/4885CXCR3 486/4885HDAC1 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.